Variations in the Lipid Profile of Patients with Chronic Renal Failure, Treated with Folic Acid

2003 ◽  
Vol 73 (3) ◽  
pp. 215-220 ◽  
Author(s):  
de Gómez Dumm ◽  
Giammona ◽  
Touceda
Keyword(s):  
Renal Failure ◽  
Folic Acid ◽  
Chronic Renal Failure ◽  
Density Lipoprotein ◽  
Plasma Homocysteine ◽  
Lipid Profiles ◽  
Erythrocyte Membranes ◽  
Favorable Effect ◽  
High Dose ◽  
Acid Therapy

Dyslipidemia and increases in plasma homocysteine usually occur at end-stage renal disease; both are recognized as risk factors for atherosclerosis. Folate administration reduces homocysteine concentration. In this study we determined the effect of a high dose of folic acid (40 mg intravenous injection three times a week) on plasma and red blood cell lipid profiles in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (baseline) and after 21, 42, and 64 days of treatment. Folic acid supplementation decreased plasma homocysteine. Plasma triglyceride levels decreased whereas polyunsaturated fatty acid values increased after 21 days; then they returned to baseline levels at the end of treatment. Total cholesterol and low-density lipoprotein (LDL) cholesterol were higher than those of the baseline during all the study, whereas high-density lipoprotein (HDL) cholesterol was reduced. In erythrocyte membranes, folic acid therapy enhanced cholesterol/phospholipid ratios and the fluorescence anisotropy of diphenyl-hexatriene. We conclude that large doses of folic acid produce a favorable effect, reducing plasma homocysteine levels and protecting patients from atherosclerosis. However, as this therapy induces significant alterations in both plasma and erythrocyte membrane lipid profiles, plasma lipid values should be controlled throughout the treatment of patients with renal failure.

Reduction of plasma homocysteine by folic acid in children with chronic renal failure

2002 ◽  
Vol 17 (7) ◽  
pp. 511-514 ◽  
Author(s):  
Hee Kang ◽  
Byong Lee ◽  
Hyewon Hahn ◽  
Jun Lee ◽  
Il Ha ◽  
...  
Keyword(s):  
Renal Failure ◽  
Folic Acid ◽  
Chronic Renal Failure ◽  
Plasma Homocysteine

Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure

Nephrology ◽  
2006 ◽  
Vol 11 (2) ◽  
pp. 137-141 ◽  
Author(s):  
AMELIA R BERNASCONI ◽  
ANDRES LISTE ◽  
NOEMI DEL PINO ◽  
GUILLERMO J ROSA DIEZ ◽  
RICARDO M HEGUILEN
Keyword(s):  
Renal Failure ◽  
Folic Acid ◽  
Chronic Renal Failure ◽  
Plasma Homocysteine

Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences

2006 ◽  
Vol 290 (2) ◽  
pp. F262-F272 ◽  
Author(s):  
N. D. Vaziri
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Hepatic Lipase ◽  
Low Density Lipoprotein ◽  
Plasma Concentrations ◽  
Cholesterol Acyltransferase ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Triglyceride Rich Lipoprotein ◽  
Density Lipoprotein Receptor

Chronic renal failure (CRF) results in profound lipid disorders, which stem largely from dysregulation of high-density lipoprotein (HDL) and triglyceride-rich lipoprotein metabolism. Specifically, maturation of HDL is impaired and its composition is altered in CRF. In addition, clearance of triglyceride-rich lipoproteins and their atherogenic remnants is impaired, their composition is altered, and their plasma concentrations are elevated in CRF. Impaired maturation of HDL in CRF is primarily due to downregulation of lecithin-cholesterol acyltransferase (LCAT) and, to a lesser extent, increased plasma cholesteryl ester transfer protein (CETP). Triglyceride enrichment of HDL in CRF is primarily due to hepatic lipase deficiency and elevated CETP activity. The CRF-induced hypertriglyceridemia, abnormal composition, and impaired clearance of triglyceride-rich lipoproteins and their remnants are primarily due to downregulation of lipoprotein lipase, hepatic lipase, and the very-low-density lipoprotein receptor, as well as, upregulation of hepatic acyl-CoA cholesterol acyltransferase (ACAT). In addition, impaired HDL metabolism contributes to the disturbances of triglyceride-rich lipoprotein metabolism. These abnormalities are compounded by downregulation of apolipoproteins apoA-I, apoA-II, and apoC-II in CRF. Together, these abnormalities may contribute to the risk of arteriosclerotic cardiovascular disease and may adversely affect progression of renal disease and energy metabolism in CRF.

Effect of Hemodialysis on the Content of Fatty Acids in Monolayers of Erythrocyte Membranes in Patients with Chronic Renal Failure

Renal Failure ◽  
2007 ◽  
Vol 29 (4) ◽  
pp. 447-452 ◽  
Author(s):  
Barbara Dolegowska ◽  
Ewa Kwiatkowska ◽  
Teresa Wesolowska ◽  
Joanna Bober ◽  
Dariusz Chlubek ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Erythrocyte Membranes

scholarly journals BIOCHEMICAL EVALUATION OF CHRONIC CONSUMPTION OF MONOSODIUM GLUTAMATE ON LIVER OF WISTAR ALBINO RATS

2021 ◽  
pp. 99-102
Author(s):  
SURENDRA BABU THANGACHI ◽  
VARSHA SRIRAM MOKHASI ◽  
SHABINA KOMATH CHENOLY
Keyword(s):  
Blood Serum ◽  
Total Cholesterol ◽  
Total Bilirubin ◽  
Liver Enzymes ◽  
Monosodium Glutamate ◽  
Density Lipoprotein ◽  
Lipid Profiles ◽  
Albino Rats ◽  
High Dose ◽  
Wistar Albino Rats

Objective: The objective of this study was to determine if there were any harmful effects of monosodium glutamate (MSG) on the liver of Wistar albino rats chronically at three different doses, namely, low, mid, and high doses equivalent to human consumption doses in developing countries. Methods: The Wistar albino rats (n=24) were divided into four groups, namely control, Low dose MSG (180 mg/kg), Mid dose MSG (360 mg/kg), and High dose MSG (720 mg/kg). At the end of the experimental period (120 days), animal blood was collected retro-orbitally to analyze the liver enzymes such as aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), Total protein, Albumin, and Total Bilirubin in blood serum. Lipid profiles, namely, Triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and Total cholesterol were subjected to analysis using blood serum. Results: Significant increase (p<0.05) in AST, ALT, ALP, and total bilirubin in serum of MSG induced low, mid, and high dose groups when compared to control group were recorded. There was a significant increase (p<0.05) in LDL, decrease in HDL, increase in total cholesterol and triglycerides of MSG-induced animal groups. Conclusion: The effects of MSG on serum liver enzymes and lipid profiles in this present animal study were not severely alarming even though the dosage was chronic which opens further discussion on the controversies revolving around MSG.

scholarly journals Relationship of Nutritional Substance toward HB Content of Chronic Kidney Failure Patients which Running Hemodialysis

2019 ◽  
Vol 9 (1) ◽  
pp. 1145-1450
Keyword(s):  
Renal Failure ◽  
Folic Acid ◽  
Chronic Renal Failure ◽  
Vitamin C ◽  
Chronic Kidney Failure ◽  
Cross Sectional Study ◽  
Research Subjects ◽  
Chi Square ◽  
Cross Sectional ◽  
The Relationship

Chronic Renal Failure (CRF) is a disease caused due to kidney damage or deterioration glomerulus filtrate rate (GFR/GFR/Glomerular Filtration Rate) <60 ml/min /1.73 m2 for ≥ 3 months. One of the complications that often appears in CRF is anemia or decrease of hemoglobin level in the blood that is related to the relationship intake of nutrients (protein, vitamin C, folic acid and iron). The purpose of this study was to determine the relationship Intake of nutrients (protein, vitamin C, folic acid and iron) on Hb levels of chronic renal failure patients undergoing hemodialysis in RSI Siti Khadijah Palembang. This type of research is an observational analytic with a cross-sectional study design. Population in this study were all outpatients with chronic renal failure undergoing hemodialysis in RSI Siti Khadijah Palembang with total research subjects were 50 subjects, taken using purposive sampling and analyzed using chi-square test. The result showed that there are 52% of patients with chronic renal failure are male more than female. The aged 50-64 years old is 44% and 30-49 years old are 32%. The percentage of outpatients who had an adequate intake of protein, vitamin C, folic acid and iron were 28%, 10%, 0%, and 18% respectively, meanwhile, most of the patients had low hemoglobin levels which were 94%. There was not a significant association between intake of nutrients (protein, vitamin C, folic acid and iron) on Hb levels of chronic renal failure patients undergoing hemodialysis in RSI Siti Khadijah Palembang. Based on these results, should be noted again nutrient intake (protein, vitamin C, folic acid and iron) outpatient before and after undergoing hemodialysis to support the optimal outcome of hemodialysis therapy.

Role of High-Dose Intravenous Frusemide Therapy in the Management of Chronic Renal Failure

1975 ◽  
Vol 3 (4) ◽  
pp. 245-250
Author(s):  
Mam Chandra ◽  
M K Mitra ◽  
N N Gupta
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Side Effects ◽  
Treated Group ◽  
Fixed Dose ◽  
High Dose ◽  
Dose Regime ◽  
Diuretic Response ◽  
High Doses

The results of using high doses of intravenous frusemide in the management of 28 patients suffering from chronic renal failure are presented. The results are compared with those obtained from 14 patients also suffering from chronic renal failure, who received identical ‘conservative management’ but were not treated with diuretics. Large doses of intravenous frusemide produced a satisfactory diuretic response in a higher percentage of treated patients (71%) compared with controls (36%). It was also observed that in the treated group of patients a significant diuretic response could be obtained in patients with a creatinine clearance below 4 ml per minute. The study also demonstrated that in the group of patients receiving frusemide the response was better in those who were given a progressive-dose regime; 88% of patients improved with this regime compared with 68% of patients who were treated with a fixed dose of frusemide. Transient deafness with tinnitus and vertigo were the only side-effects observed. However these effects were only seen in patients who received 1000 mg or more frusemide in one day, administered over a period of one to two hours. It is concluded that all patients suffering from chronic renal failure should be given a trial of large doses of intravenous frusemide therapy, along with other conventional measures, particularly where facilities for dialysis are not immediately available.

Amino Acid Therapy for Patients with Chronic Renal Failure

1987 ◽  
Vol 14 (5) ◽  
pp. 8-11
Author(s):  
J. Bergström ◽  
M. Ahlberg ◽  
A. Alvestrand ◽  
P. Fürst
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Amino Acid ◽  
Acid Therapy

ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure

2004 ◽  
Vol 287 (5) ◽  
pp. F1038-F1043 ◽  
Author(s):  
N. D. Vaziri ◽  
K. Liang
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Total Cholesterol ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cholesterol Ratio ◽  
Vldl Cholesterol ◽  
Plasma Lcat ◽  
Acat Inhibitor ◽  
Lcat Deficiency

Chronic renal failure (CRF) is associated with increased risk of arteriosclerotic cardiovascular disease and profound alteration of plasma lipid profile. Uremic dyslipidemia is marked by increased plasma concentration of ApoB-containing lipoproteins and impaired high-density lipoprotein (HDL)-mediated reverse cholesterol transport. These abnormalities are, in part, due to acquired LCAT deficiency and upregulation of hepatic acyl-CoA:cholesterol acyltransferase (ACAT). ACAT catalyzes intracellular esterification of cholesterol, thereby promoting hepatic production of ApoB-containing lipoproteins and constraining HDL-mediated cholesterol uptake in the peripheral tissues. In view of the above considerations, we tested the hypothesis that pharmacological inhibition of ACAT may ameliorate CRF-induced dyslipidemia. 5/6 Nephrectomized rats were treated with either ACAT inhibitor IC-976 (30 mg·kg−1·day−1) or placebo for 6 wk. Sham-operated rats served as controls. Key cholesterol-regulating enzymes, plasma lipids, and creatinine clearance were measured. The untreated CRF rats exhibited increased plasma low-density lipoprotein (LDL) and very LDL (VLDL) cholesterol, unchanged plasma HDL cholesterol, elevated total cholesterol-to-HDL cholesterol ratio, reduced liver microsomal free cholesterol, and diminished creatinine clearance. This was accompanied by reduced plasma LCAT, increased hepatic ACAT-2 mRNA, ACAT-2 protein and ACAT activity, and unchanged hepatic HMG-CoA reductase and cholesterol 7α-hydroxylase. ACAT inhibitor raised plasma HDL cholesterol, lowered LDL and VLDL cholesterol, and normalized total cholesterol-to-HDL cholesterol ratio without changing total cholesterol concentration (hence, a shift from ApoB-containing lipoproteins to HDL). This was accompanied by normalizations of hepatic ACAT activity and plasma LCAT. In conclusion, inhibition of ACAT reversed LCAT deficiency and improved plasma HDL level in CRF rats. Future studies are needed to explore the efficacy of ACAT inhibition in humans with CRF.

Sign in / Sign up

Export Citation Format

Share Document